Literature DB >> 1312964

Effect of free fatty acids on insulin receptor binding and tyrosine kinase activity in hepatocytes isolated from lean and obese rats.

J Svedberg1, P Björntorp, U Smith, P Lönnroth.   

Abstract

We demonstrated previously that high physiological concentrations of free fatty acids (FFA) rapidly decrease insulin binding, degradation, and action in isolated rat hepatocytes. In this study, hepatocytes from lean and obese Sprague-Dawley rats (Alab, Stockholm) were preincubated with or without 0.4 mM oleic acid, and the effect on insulin binding and tyrosine kinase activity was measured. In the absence of exogenous FFA, insulin binding was reduced in hepatocytes from obese compared with lean rats (mean +/- SE reduction 44 +/- 7%, n = 8, P less than 0.01). Furthermore, the inhibitory effect of oleic acid added to hepatocytes from lean rats (n = 8; 40 +/- 9%, P less than 0.01) was not seen in cells from obese rats. Treating obese rats with Etomoxir, a carnitine palmitoyl transferase I inhibitor, increased insulin binding to isolated hepatocytes by 41 +/- 13% (n = 5, P less than 0.05). There was no difference in total binding to partially purified insulin receptors from solubilized hepatocytes from lean and obese rats, whether cells were or were not preincubated with oleic acid. Tyrosine kinase activity of partially purified receptors from basal or insulin-stimulated cells was not affected by either obesity, treatment with Etomoxir, or preincubating the cells with oleic acid. Thus, both obesity and elevated ambient FFA levels are associated with impaired insulin cell surface binding to isolated hepatocytes, possibly through an effect of lipid oxidation on the internalization/recycling of the insulin-receptor complex without any perturbation of the receptor tyrosine kinase activity. The data suggest that the reduced insulin binding to hepatocytes from obese rats is due to elevated ambient FFA levels.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312964     DOI: 10.2337/diab.41.3.294

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  6 in total

1.  A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM.

Authors:  G Paolisso; P A Tataranni; J E Foley; C Bogardus; B V Howard; E Ravussin
Journal:  Diabetologia       Date:  1995-10       Impact factor: 10.122

Review 2.  Mitochondrial dysfunction and insulin resistance from the outside in: extracellular matrix, the cytoskeleton, and mitochondria.

Authors:  Dawn K Coletta; Lawrence J Mandarino
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-08-23       Impact factor: 4.310

3.  The biochemical basis of increased hepatic glucose production in a mouse model of type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  S Andrikopoulos; J Proietto
Journal:  Diabetologia       Date:  1995-12       Impact factor: 10.122

4.  Role of lipids in development of noninsulin-dependent diabetes mellitus: lessons learned from Pima Indians.

Authors:  P A Tataranni; L J Baier; G Paolisso; B V Howard; E Ravussin
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

5.  Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity.

Authors:  A Dresner; D Laurent; M Marcucci; M E Griffin; S Dufour; G W Cline; L A Slezak; D K Andersen; R S Hundal; D L Rothman; K F Petersen; G I Shulman
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

6.  β-Cell function improvements in grade I/II obese subjects with type 2 diabetes 1 month after biliopancreatic diversion: results from modeling analyses of oral glucose tolerance tests and hyperglycemic clamp studies.

Authors:  Ana Carolina Junqueira Vasques; José Carlos Pareja; Maria da Saude de Oliveira; Fernanda Satake Novaes; Marcelo Miranda de Oliveira Lima; Élinton A Chaim; Francesca Piccinini; Chiara Dalla Man; Claudio Cobelli; Bruno Geloneze
Journal:  Diabetes Care       Date:  2013-10-17       Impact factor: 19.112

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.